Valproic acid promotes radiosensitization in meningioma stemlike cells

Oncotarget

Volumn 6, Issue 12, 2015, Pages 9959-9969

  Chiou, Hsin Ying Clair ^a   Lai, Wen Kuo ^b   Huang, Li Chun ^b   Huang, Shih Ming ^b   Chueh, Sheau Huei ^b   Ma, Hsin I ^a   Hueng, Dueng Yuan ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Meningioma; Oct4; Radiosensitization; Tumor stem like cells; Valproic acid

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; HISTONE H2AX; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; VALPROIC ACID; POU5F1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL ADHESION; CELL CYCLE ARREST; CELL VIABILITY; CHEMORADIOTHERAPY; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; HUMAN; HUMAN CELL; MENINGIOMA; MENINGIOMA SPHERE CELL; MENINGIOMA STEM LIKE CELL; MOLECULARLY TARGETED THERAPY; OCT4 GENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; DOWN REGULATION; DRUG EFFECTS; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; DOWN-REGULATION; HUMANS; MENINGIOMA; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RADIATION TOLERANCE; VALPROIC ACID;

EID: 84929593716     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3692     Document Type: Article

References (49)

1. Jordan CT, Guzman ML and Noble M. Cancer stem cells. The New England Journal of Medicine. 2006, 355:1253-1261.
2. Gutmann DH. The taxonomy of brain cancer stem cells:what's in a name? Oncoscience. 2014, 1:241-247.
3. Hueng DY, Sytwu HK, Huang SM, Chang C and Ma HI. Isolation and characterization of tumor stem-like cells from human meningiomas. Journal of Neuro-Oncology. 2011, 104:45-53.
4. Tang H, Gong Y, Mao Y, Xie Q, Zheng M, Wang D, Zhu H, Wang X, Chen H, Chen X and Zhou L. CD133- positive cells might be responsible for efficient proliferation of human meningioma cells. International Journal of Molecular Sciences. 2012, 13:6424-6439.
5. Rath P, Miller DC, Litofsky NS, Anthony DC, Feng Q, Franklin C, Pei L, Free A, Liu J, Ren M, Kirk MD and Shi H. Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma. Experimental and Molecular Pathology. 2011; 90:179-188.
6. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, Martinelli C, Lusis EA, Hegedus B, Gutmann DH and Giovannini M. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene. 2011, 30:2333-2344.
7. Yoo-Jin K, Kim Y, Bochem N, Ketter R, Henn W and Feiden W. Meningiomas: multiparametric approach for risk stratification and grading. Der Pathologe. 2008; 29:428-433.
8. Ferraro DJ, Funk RK, Blackett JW, Ju MR, Dewees TA, Chicoine MR, Dowling JL, Rich KM, Drzymala RE, Zoberi I, Simpson JR and Jaboin JJ. A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas. Radiat Oncol. 2014, 9:38.
9. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H and Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. Journal of Neurology. 2009, 256:1519-1526.
10. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO Journal. 2001, 20:6969-6978.
11. Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, Kitagawa H, Fushida S, Harada S, Fujimura T and Ohta T. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. International Journal of Oncology. 2012, 40:2140-2146.
12. Liu X, Chen L, Sun F and Zhang G. Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action. Cytotechnology. 2013, 65:597-608.
13. Yang FQ, Liu M, Yang FP, Che J, Li W, Zhai W, Wang GC, Zheng JH and Li X. VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1alpha. Molecular Biology Reports. 2014, 41:1511-1518.
14. Wang D, Jing Y, Ouyang S, Liu B, Zhu T, Niu H and Tian Y. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents and. Oncology Letters. 2013, 6:1492-1498.
15. Moreaux J, Reme T, Leonard W, Veyrune JL, Requirand G, Goldschmidt H, Hose D and Klein B. Gene expressionbased prediction of myeloma cell sensitivity to histone deacetylase inhibitors. British Journal of Cancer. 2013, 109:676-685.
16. Han BR, You BR and Park WH. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncology Reports. 2013, 30:2999-3005.
17. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E and Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treatment Reviews. 2008, 34:206-222.
18. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H and Scholer HR. Direct reprogramming of human neural stem cells by OCT4. Nature. 2009, 461:649-643.
19. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR, Gronemeyer H and Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Medicine. 2005, 11:77-84.
20. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine. 2005, 11:71-76.
21. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW and Sytwu HK. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. Journal of Neurosurgery. 2011, 114:651-662.
22. Sharma A, Singh K and Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012; 920:613-626.
23. Cinatl J, Jr., Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW and Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anti-cancer Drugs. 1996, 7:766-773.
24. Roy Choudhury S, Karmakar S, Banik NL and Ray SK. Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells. Neurochemical Research. 2011, 36:2292-2305.
25. Gan CP, Hamid S, Hor SY, Zain RB, Ismail SM, Wan Mustafa WM, Teo SH, Saunders N and Cheong SC. Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head & Neck. 2012, 34:344-353.
26. Haghpanah V, Malehmir M, Larijani B, Ahmadian S, Alimoghaddam K, Heshmat R, Ghavamzadeh A, Adabi K and Ghaffari SH. The Beneficial Effects of Valproic Acid in Thyroid Cancer Are Mediated through Promoting Redifferentiation and Reducing Stemness Level: An In Vitro Study. Journal of Thyroid Research. 2014, 2014:218763.
27. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012, 18:408-416.
28. Alvarez AA, Field M, Bushnev S, Longo MS and Sugaya K. The Effects of Histone Deacetylase Inhibitors on Glioblastoma-Derived Stem Cells. Journal of Molecular Neuroscience. 2015, 55:7-20
29. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE and Melton DA. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nature Biotechnology. 2008, 26:795-797.
30. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T, Boehrer S, Hoelzer D, Ottmann OG and Ruthardt M. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Research. 2005, 65:2537-2541.
31. Teng HF, Kuo YL, Loo MR, Li CL, Chu TW, Suo H, Liu HS, Lin KH and Chen SL. Valproic acid enhances Oct4 promoter activity in myogenic cells. Journal of Cellular Biochemistry. 2010, 110:995-1004.
32. Teng HF, Li PN, Hou DR, Liu SW, Lin CT, Loo MR, Kao CH, Lin KH and Chen SL. Valproic acid enhances Oct4 promoter activity through PI3K/Akt/mTOR pathway activated nuclear receptors. Molecular and Cellular Endocrinology. 2014, 383:147-158.
33. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA and Woodward WA. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/beta-catenin signaling. Stem Cells. 2012, 30:2366-2377.
34. Kuendgen A and Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer. 2007, 110:943-954.
35. Kawagoe R, Kawagoe H and Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leukemia Research. 2002, 26:495-502.
36. Fu J, Shao CJ, Chen FR, Ng HK and Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro-Oncology. 2010, 12:328-340.
37. Chen X, Wong P, Radany E and Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biotherapy & Radiopharmaceuticals. 2009, 24:689-699.
38. Chen X, Wong JY, Wong P and Radany EH. Lowdose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Molecular Cancer Research : MCR. 2011, 9:448-461.
39. Zhou Y, Xu Y, Wang H, Niu J, Hou H and Jiang Y. Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line. Oncology Letters. 2014, 7:203-208.
40. Jokinen E, Laurila N, Koivunen P and Koivunen JP. Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. Oncotarget. 2014, 5:9295-9307.
41. Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S and Duenas-Gonzalez A. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011, 28 Suppl 1:S540-546.
42. Lamb R, Ozsvari B, Lisanti CL, Tanowitz HB, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget. 2015.
43. Huang SP, Huang CH, Shyu JF, Lee HS, Chen SG, Chan JY and Huang SM. Promotion of wound healing using adiposederived stem cells in radiation ulcer of a rat model. Journal of Biomedical Science. 2013, 20:51.
44. Huang SP, Hsu CC, Chang SC, Wang CH, Deng SC, Dai NT, Chen TM, Chan JY, Chen SG and Huang SM. Adipose-derived stem cells seeded on acellular dermal matrix grafts enhance wound healing in a murine model of a full-thickness defect. Annals of Plastic Surgery. 2012, 69:656-662.
45. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, Liu LW, Wei HW and Lee HM. Nodal promotes growth and invasion in human gliomas. Oncogene. 2010, 29:3110-3123.
46. Tsai WC, Chen Y, Huang LC, Lee HS, Ma HI, Huang SM, Sytwu HK and Hueng DY. EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas. Journal of Neuro-Oncology. 2013, 114:281-290.
47. Hueng DY, Lin GJ, Huang SH, Liu LW, Ju DT, Chen YW, Sytwu HK, Chang C, Huang SM, Yeh YS, Lee HM and Ma HI. Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. Journal of Neuro-Oncology. 2011, 104:21-31.
48. Amini S, Fathi F, Mobalegi J, Sofimajidpour H and Ghadimi T. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anatomy & Cell Biology. 2014, 47:1-11.
49. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC and Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011, 17:589-597.